Twist Bioscience Corp (TWST) Stock
1 member of Congress disclosed 2 trades in TWST since 2020: 1 purchase and 1 sale, most recently Dwight Evans (sale, Mar 30, 2022). 6 of the hedge funds AlphaScala tracks reported TWST in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $468.08M. Company insiders reported 0 open-market buys and 75 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which members of Congress traded Twist Bioscience Corp (TWST)?
Most recent: Dwight Evans (sale, Mar 30, 2022); records start Mar 2, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dwight Evans D-PA · House | 2022-03-30 | sale | $1k – $15k |
| Dwight Evans D-PA · House | 2020-03-02 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all TWST political trades →Which hedge funds own TWST?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 4.55M | $468.08M | -28% |
| D.E. Shaw David Shaw | 1.19M | $121.98M | +2442% |
| Citadel Ken Griffin | 862K | $88.69M | -29% |
| Marshall Wace | 397K | $40.83M | NEW |
| Millennium Management Israel Englander | 347K | $35.71M | -1% |
| Bridgewater Associates Ray Dalio | 19K | $1.92M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Twist Bioscience Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 3, 26 | Werner Robert F. | Chief Accounting Officer | SELL | 148 | $20K |
| Nov 3, 26 | Leproust Emily M. | Chief Executive Officer | SELL | 4.6K | $619K |
| Nov 3, 26 | Green Paula | SVP of Human Resources | SELL | 1.0K | $136K |
| Nov 3, 26 | Finn Patrick John | President and COO | SELL | 2.6K | $347K |
| Nov 3, 26 | Cho Dennis | See Remarks | SELL | 949 | $128K |
| Oct 23, 26 | Finn Patrick John | President and COO | SELL | 2.2K | $302K |
| Oct 9, 26 | Laponis Adam | Chief Financial Officer | SELL | 2.5K | $385K |
| Oct 5, 26 | Leproust Emily M. | Chief Executive Officer | SELL | 1.8K | $369K |
| Oct 5, 26 | Leproust Emily M. | Chief Executive Officer | SELL | 481 | $97K |
| Oct 5, 26 | Leproust Emily M. | Chief Executive Officer | SELL | 1.0K | $206K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →TWST price chart
Powered by TradingViewWhat does Twist Bioscience Corp do?
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells synthetic DNA-based products through a proprietary semiconductor-based platform. This disruptive technology synthesizes DNA on silicon chips rather than traditional plastic plates, enabling high-quality, high-throughput production that is faster and more cost-effective for large-scale applications. The company offers synthetic genes and gene fragments for therapeutics, diagnostics, chemicals and materials, food and agriculture, data storage, and academic research, serving biotech, pharmaceutical, industrial chemical, agricultural firms, and labs. Additional products include oligo pools for targeted next-generation sequencing (NGS), CRISPR gene editing, mutagenesis, DNA origami, DNA computing, and other advanced uses. Twist Bioscience also provides specialized services such as in vivo antibody discovery with humanized transgenic mouse models and customizable oncology DNA comprehensive genomic profiling (CGP) panels that are platform-agnostic for precision medicine. Recent expansions include express delivery for all gene fragments, collaborations for NGS workflows in agrigenomics, and end-to-end solutions with partners. Headquartered in South San Francisco, California, Twist Bioscience operates across the Americas, EMEA, and APAC regions, playing a pivotal role in accelerating biological engineering and innovation in life sciences.